Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
The price of Surgery Partners Inc (NASDAQ: SGRY) closed at $15.71 in the last session, up 0.45% from day before closing price of $15.64. In other words, the price has increased by $0.45 from its previous closing price. On the day, 2.27 million shares were traded. SGRY stock price reached its highest trading level at $16.28 during the session, while it also had its lowest trading level at $15.4519.
Ratios:
We take a closer look at SGRY’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 9.99 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 10.47. For the most recent quarter (mrq), Quick Ratio is recorded 1.72 and its Current Ratio is at 1.88. In the meantime, Its Debt-to-Equity ratio is 2.24 whereas as Long-Term Debt/Eq ratio is at 2.15.
On December 16, 2024, BofA Securities started tracking the stock assigning a Buy rating and target price of $30.BofA Securities initiated its Buy rating on December 16, 2024, with a $30 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Oct 24 ’25 when Wayne DeVeydt bought 2,913 shares for $22.30 per share.
Wayne DeVeydt bought 30,948 shares of SGRY for $666,210 on Oct 23 ’25. On Oct 22 ’25, another insider, Wayne DeVeydt, who serves as the former director of the company, bought 25,052 shares for $21.27 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SGRY now has a Market Capitalization of 2031959296 and an Enterprise Value of 7523727360. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 28.52. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.62 while its Price-to-Book (P/B) ratio in mrq is 1.17. Its current Enterprise Value per Revenue stands at 2.288 whereas that against EBITDA is 11.246.
Stock Price History:
The Beta on a monthly basis for SGRY is 1.98, which has changed by -0.24261498 over the last 52 weeks, in comparison to a change of 0.1877265 over the same period for the S&P500. Over the past 52 weeks, SGRY has reached a high of $26.16, while it has fallen to a 52-week low of $14.94. The 50-Day Moving Average of the stock is -8.07%, while the 200-Day Moving Average is calculated to be -24.83%.
Shares Statistics:
According to the various share statistics, SGRY traded on average about 1.82M shares per day over the past 3-months and 1066040 shares per day over the past 10 days. A total of 129.02M shares are outstanding, with a floating share count of 77.56M. Insiders hold about 40.03% of the company’s shares, while institutions hold 79.69% stake in the company. Shares short for SGRY as of 1765756800 were 14484597 with a Short Ratio of 7.97, compared to 1763078400 on 14211341. Therefore, it implies a Short% of Shares Outstanding of 14484597 and a Short% of Float of 23.52.
Earnings Estimates
A comprehensive evaluation of Surgery Partners Inc (SGRY) is underway, with the input of 9.0 analysts contributing to its current rating.The consensus estimate for the next quarter is -$0.01, with high estimates of $0.01 and low estimates of -$0.04.
Analysts are recommending an EPS of between $0.69 and $0.54 for the fiscal current year, implying an average EPS of $0.64. EPS for the following year is $0.69, with 10.0 analysts recommending between $0.92 and $0.24.
Revenue Estimates
According to 11 analysts, . The current quarter’s revenue is expected to be $866.54M. It ranges from a high estimate of $889M to a low estimate of $851.3M. As of . The current estimate, Surgery Partners Inc’s year-ago sales were $864.4MFor the next quarter, 11 analysts are estimating revenue of $823.15M. There is a high estimate of $854M for the next quarter, whereas the lowest estimate is $805.8M.
A total of 11 analysts have provided revenue estimates for SGRY’s current fiscal year. The highest revenue estimate was $3.31B, while the lowest revenue estimate was $3.27B, resulting in an average revenue estimate of $3.29B. In the same quarter a year ago, actual revenue was $3.11BBased on 11 analysts’ estimates, the company’s revenue will be $3.56B in the next fiscal year. The high estimate is $3.67B and the low estimate is $3.42B.
